Holen Sie sich die Stockscreener-App
1.40
0.00%
0.00
Schlusskurs vom Vortag:
$1.40
Offen:
$1.4
24-Stunden-Volumen:
51,457
Relative Volume:
0.70
Marktkapitalisierung:
$8.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.3509
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
+4.48%
1M Leistung:
-6.67%
6M Leistung:
-24.32%
1J Leistung:
-64.29%
1-Tages-Spanne:
$1.39
$1.45
1-Wochen-Bereich:
$1.31
$1.49
52-Wochen-Spanne:
$1.31
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.40 | 8.16M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Will Aprea Therapeutics Inc. stock outperform value stocksWeekly Gains Report & Consistent Profit Alerts - newser.com
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge - openPR.com
Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside - FinancialContent
Aprea Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Is Aprea Therapeutics Inc. stock attractive for growth ETFsJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - newser.com
Tools to assess Aprea Therapeutics Inc.’s risk profileJuly 2025 Selloffs & Trade Opportunity Analysis Reports - newser.com
Is Aprea Therapeutics Inc. stock poised for growthPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Why Aprea Therapeutics Inc. stock could outperform in 2025Trade Exit Summary & Low Risk High Win Rate Picks - newser.com
Risk vs reward if holding onto Aprea Therapeutics Inc.Portfolio Risk Summary & Free Technical Pattern Based Buy Signals - newser.com
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Aprea Therapeutics, Inc. (APRE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Aprea Therapeutics, Inc.Common Stock (Nasdaq:APRE) Stock Quote | PRN_FinancialWrapper | PR Newswire - FinancialContent
How Aprea Therapeutics Inc. stock reacts to global recession fearsQuarterly Investment Review & Verified Technical Trade Signals - Fundação Cultural do Pará
Will Aprea Therapeutics Inc. stock outperform tech sector in 2025Market Performance Report & Low Drawdown Investment Ideas - fcp.pa.gov.br
Meme Stocks: How Aprea Therapeutics Inc. stock performs in weak economy2025 Earnings Surprises & Accurate Technical Buy Alerts - Fundação Cultural do Pará
Update Recap: Will Aprea Therapeutics Inc. stock deliver shareholder value2025 Earnings Surprises & Low Risk Entry Point Tips - fcp.pa.gov.br
Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors - TipRanks
Aprea’s WEE1 inhibitor shows disease stabilization in early trial - Investing.com
Aprea’s WEE1 inhibitor shows disease stabilization in early trial By Investing.com - Investing.com South Africa
Aprea Therapeutics Reports Promising Trial Results for APR-1051 - TipRanks
Aprea sees early activity in APR-1051 Wee1 trial - MarketScreener
Aprea Therapeutics Provides Clinical Update on ACESOT-1051 Trial - TradingView
Aprea Therapeutics Reports Promising Early Results for APR-1051 in Phase 1 Trial for Advanced Solid Tumors at AACR-NCI-EORTC Conference - Quiver Quantitative
Aprea Therapeutics IncDose Escalation Cont - 富途牛牛
Aprea Therapeutics (NASDAQ: APRE) advances APR-1051; three of four stable at 100 mg - Stock Titan
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):